How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Belantamab mafodotin is not recommended, within its marketing authorisation, for treating multiple myeloma in adults who:

  • have had 4 or more previous treatments and

  • whose cancer is refractory to at least:

    • 1 proteasome inhibitor

    • 1 immunomodulatory drug, and

    • 1 anti-CD38 monoclonal antibody, and

  • whose cancer progressed on the last treatment.

1.2 This recommendation is not intended to affect treatment with belantamab mafodotin that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

There is no standard treatment for multiple myeloma after 4 or more treatments, when those treatments include at least 1 proteasome inhibitor, 1 immunomodulatory drug and 1 anti-CD38 monoclonal antibody. Most people have pomalidomide plus dexamethasone.

It is not clear from the clinical evidence how well belantamab mafodotin works compared with pomalidomide plus dexamethasone. This means that it is not possible to reliably estimate the cost effectiveness of belantamab mafodotin. So, it is not recommended.